European Union · Question · QUESTION_WRITTEN
E-9-2020-005767
Efficacy of remdesivir and transparency with regard to the conditions of the recent Joint Procurement Agreement
Introduced
23 October 2020
Last action
17 December 2020 · Answer
Status
answered
Sponsors
Jutta PAULUS, Kim VAN SPARRENTAK, Tilly METZ, Michèle RIVASI
Subjects
Discovery layer
Source updated
17 December 2020
Official titles
Authentic titles published by the source. The stored canonical title is not replaced.
3 official languages
German
Wirksamkeit von Remdesivir und Transparenz in Bezug auf die Bedingungen der kürzlich geschlossenen Vereinbarung über die gemeinsame Beschaffung
French
Efficacité du remdésivir et transparence en ce qui concerne les conditions du récent accord de passation conjointe de marché
Dutch
Effectiviteit van remdesivir en transparantie met betrekking tot de voorwaarden van de recente gezamenlijke aanbestedingsovereenkomst
Records
Official question E-9-2020-005767 from European Union at European Parliament. Dated 23 October 2020. Status: answered.
Timeline
23 October 2020
Written question
Efficacy of remdesivir and transparency with regard to the conditions of the recent Joint Procurement Agreement
Source: QUESTION_WRITTEN
17 December 2020
Answer
Source: QUESTION_WRITTEN_ANSWER
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
13 official files
Efficacy of remdesivir and transparency with regard to the conditions of the recent Joint Procurement Agreement
QUESTION_WRITTEN · EN · 4 November 2020
Efficacy of remdesivir and transparency with regard to the conditions of the recent Joint Procurement Agreement
QUESTION_WRITTEN · EN · 4 November 2020
Efficacy of remdesivir and transparency with regard to the conditions of the recent Joint Procurement Agreement
QUESTION_WRITTEN · EN · 4 November 2020
Answer
QUESTION_WRITTEN_ANSWER · 17 December 2020
Efficacité du remdésivir et transparence en ce qui concerne les conditions du récent accord de passation conjointe de marché
QUESTION_WRITTEN · FR · 4 November 2020
Efficacité du remdésivir et transparence en ce qui concerne les conditions du récent accord de passation conjointe de marché
QUESTION_WRITTEN · FR · 4 November 2020
Efficacité du remdésivir et transparence en ce qui concerne les conditions du récent accord de passation conjointe de marché
QUESTION_WRITTEN · FR · 4 November 2020
Effectiviteit van remdesivir en transparantie met betrekking tot de voorwaarden van de recente gezamenlijke aanbestedingsovereenkomst
QUESTION_WRITTEN · NL · 4 November 2020
Effectiviteit van remdesivir en transparantie met betrekking tot de voorwaarden van de recente gezamenlijke aanbestedingsovereenkomst
QUESTION_WRITTEN · NL · 4 November 2020
Effectiviteit van remdesivir en transparantie met betrekking tot de voorwaarden van de recente gezamenlijke aanbestedingsovereenkomst
QUESTION_WRITTEN · NL · 4 November 2020
Wirksamkeit von Remdesivir und Transparenz in Bezug auf die Bedingungen der kürzlich geschlossenen Vereinbarung über die gemeinsame Beschaffung
QUESTION_WRITTEN · DE · 4 November 2020
Wirksamkeit von Remdesivir und Transparenz in Bezug auf die Bedingungen der kürzlich geschlossenen Vereinbarung über die gemeinsame Beschaffung
QUESTION_WRITTEN · DE · 4 November 2020
Wirksamkeit von Remdesivir und Transparenz in Bezug auf die Bedingungen der kürzlich geschlossenen Vereinbarung über die gemeinsame Beschaffung
QUESTION_WRITTEN · DE · 4 November 2020
Sponsors
- · EU_COMMISSION · ADDRESSEE
- Jutta PAULUS · AUTHOR
- Kim VAN SPARRENTAK · AUTHOR
- Tilly METZ · AUTHOR
- Michèle RIVASI · AUTHOR
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.europarl.europa.eu/doceo/document/E-9-2020-005767_EN.html
- Open data entity: https://data.europarl.europa.eu/api/v2/parliamentary-questions/E-9-2020-005767
- eu · E-9-2020-005767 · source updated 17 December 2020